Cita APA

C., M., R., G., F., D., A., T., B., A., L., L., . . . I.W., F. (2022). First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: Final analysis of the randomized, phase III iLLUMINATE trial.

Citación estilo Chicago

C., Moreno, et al. First-line Treatment of Chronic Lymphocytic Leukemia With Ibrutinib Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab: Final Analysis of the Randomized, Phase III ILLUMINATE Trial. 2022.

Cita MLA

C., Moreno, et al. First-line Treatment of Chronic Lymphocytic Leukemia With Ibrutinib Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab: Final Analysis of the Randomized, Phase III ILLUMINATE Trial. 2022.